AU2004294933B2 - Biomolecule partition motifs and uses thereof - Google Patents

Biomolecule partition motifs and uses thereof Download PDF

Info

Publication number
AU2004294933B2
AU2004294933B2 AU2004294933A AU2004294933A AU2004294933B2 AU 2004294933 B2 AU2004294933 B2 AU 2004294933B2 AU 2004294933 A AU2004294933 A AU 2004294933A AU 2004294933 A AU2004294933 A AU 2004294933A AU 2004294933 B2 AU2004294933 B2 AU 2004294933B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
motif
cell
swty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2004294933A
Other languages
English (en)
Other versions
AU2004294933A1 (en
Inventor
Min Li
Sojin Shikano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2004294933A1 publication Critical patent/AU2004294933A1/en
Application granted granted Critical
Publication of AU2004294933B2 publication Critical patent/AU2004294933B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
AU2004294933A 2003-11-21 2004-11-22 Biomolecule partition motifs and uses thereof Expired - Fee Related AU2004294933B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52438003P 2003-11-21 2003-11-21
US60/524,380 2003-11-21
PCT/US2004/039285 WO2005053811A2 (en) 2003-11-21 2004-11-22 Biomolecule partition motifs and uses thereof

Publications (2)

Publication Number Publication Date
AU2004294933A1 AU2004294933A1 (en) 2005-06-16
AU2004294933B2 true AU2004294933B2 (en) 2011-11-17

Family

ID=34652267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004294933A Expired - Fee Related AU2004294933B2 (en) 2003-11-21 2004-11-22 Biomolecule partition motifs and uses thereof

Country Status (6)

Country Link
US (1) US7732165B2 (enExample)
EP (1) EP1701772A4 (enExample)
JP (1) JP4790624B2 (enExample)
CN (1) CN1997749A (enExample)
AU (1) AU2004294933B2 (enExample)
WO (1) WO2005053811A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198609A (zh) 2005-06-14 2008-06-11 先灵公司 天冬氨酰基蛋白酶抑制剂
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
EP2465925A1 (en) 2005-07-22 2012-06-20 The Board Of Trustees Of The Leland Light-activated cation channel and uses thereof
US8926959B2 (en) * 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
ES2349433T3 (es) * 2005-10-27 2011-01-03 Schering Corporation Inhibidores heterocíclicos de aspartil proteasa.
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
AU2008329529B2 (en) * 2007-11-27 2015-02-19 The University Of British Columbia 14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
EP3165534B1 (en) 2008-04-23 2018-09-26 The Board of Trustees of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
EP2610350B1 (en) 2008-05-29 2014-12-17 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
ES2612052T3 (es) 2008-06-17 2017-05-11 The Board Of Trustees Of The Leland Stanford Junior University Dispositivos para la estimulación óptica de células diana, utilizando un elemento de transmisión óptica
US10711242B2 (en) 2008-06-17 2020-07-14 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
DK2406633T3 (en) 2009-03-11 2019-04-01 Augurex Life Sciences Corp COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS
US9134323B2 (en) 2009-12-01 2015-09-15 The Rockefeller University Antibody that specifically binds to an epitope in the tureet region of a human Kir channel
CN106011073A (zh) 2010-03-17 2016-10-12 小利兰·斯坦福大学托管委员会 光敏离子透过性分子
EP3486253A1 (en) 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
US9992981B2 (en) 2010-11-05 2018-06-12 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
CA2816990A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CN103384469B (zh) 2010-11-05 2016-06-15 斯坦福大学托管董事会 光控cns功能障碍
CA2816972C (en) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
CN110215614A (zh) 2010-11-05 2019-09-10 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
CN104011068A (zh) 2011-10-21 2014-08-27 奥古雷克斯生命科学公司 衍生自瓜氨酸化的14-3-3的抗原及其在风湿性关节炎诊断中的用途
CA3036859A1 (en) 2011-12-16 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
AU2013222443B2 (en) 2012-02-21 2017-12-14 Circuit Therapeutics, Inc. Compositions and methods for treating neurogenic disorders of the pelvic floor
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
WO2014144409A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
JP6549559B2 (ja) 2013-04-29 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
EP3033427A4 (en) 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Compositions and methods for controlling pain
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CN111870700B (zh) * 2020-08-12 2021-10-19 中国科学院昆明动物研究所 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856155A (en) 1996-02-23 1999-01-05 The Johns Hopkins University School Of Medicine Compounds and related methods for modulating potassium ion channels and assays for such compounds
AU3135097A (en) 1996-05-22 1997-12-09 Johns Hopkins University, The Methods of detection utilizing modified bacteriophage
AU7410998A (en) 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
WO2001014539A2 (en) 1999-08-20 2001-03-01 Johns Hopkins University School Of Medicine Methods and compositions for the construction and use of fusion libraries
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHIMURA, N. et al. "A Di-acidic (DXE) Code Directs Concentration of Cargo during Export from the Endoplasmic Reticulum". J. BIOL. CHEM. (1999), 274(22), 15937-15946. *

Also Published As

Publication number Publication date
JP2007525207A (ja) 2007-09-06
WO2005053811A2 (en) 2005-06-16
CN1997749A (zh) 2007-07-11
JP4790624B2 (ja) 2011-10-12
US20070031924A1 (en) 2007-02-08
EP1701772A4 (en) 2012-03-28
WO2005053811A3 (en) 2007-03-29
EP1701772A2 (en) 2006-09-20
US7732165B2 (en) 2010-06-08
AU2004294933A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
AU2004294933B2 (en) Biomolecule partition motifs and uses thereof
KR102622245B1 (ko) 근육 성능 개선 화합물
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
SG172692A1 (en) Pan-cell surface receptor- specific therapeutics
JP4969006B2 (ja) 神経細胞死を抑制するポリペプチド、Ｈｕｍａｎｉｎ
WO2009125646A1 (ja) Ｔｄｐ－４３蓄積細胞モデル
JP2001505407A (ja) 腫瘍壊死因子関連リガンド
EP2328917B1 (en) Neuronal viability factor and use thereof
WO2010011952A2 (en) Highly potent peptides to control cancer and neurodegenerative diseases
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
KR20230169124A (ko) Actrii-alk4 길항제 및 심부전을 치료하는 방법
US20040120955A1 (en) D1-1 nucleic acids, polypeptides and related methods
KR101625112B1 (ko) 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
RU2846293C1 (ru) АНТИТЕЛО К EphA4
JPWO2005049833A1 (ja) Ｇ蛋白質共役型受容体をコードする遺伝子およびその遺伝子産物
US20030119726A1 (en) P-glycoproteins and uses thereof
US20240317867A1 (en) Igfr-like 2 receptor and uses thereof
WO2007108557A1 (ja) Ｉｐ３受容体結合タンパク質による細胞内標的分子の制御
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
KR20230123923A (ko) 항-EphA4 항체
WO2004106370A1 (en) M11l derived peptides and therapeutic use thereof
US20190330291A1 (en) TGFß INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT
JP4283531B2 (ja) マスト細胞の細胞死誘発剤
TW202528337A (zh) 包括細胞穿透藥劑之方法、組合物、及套組

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee